Skip to main content

Verona Pharma plc

VRNADelisted Oct 7, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001657312

Verona Pharma plc was delisted on Oct 7, 2025; its insiders filed their last Form 4 on Oct 8, 2025; 243 institutions reported holding it in 13F filings for Q3 2025, worth $8.57B in total; superinvestors Duquesne Family Office and Soros Fund Management held it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 8, 2026, 1:52 PM ET

Revenue flow, FY2024

Where the revenue went in FY2024, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Net loss for FY2024: $173.4M (410.2% of revenue).

Income statement

Each column is one fiscal year, newest first.

Income statement of Verona Pharma plc, annual
Line itemFY2024FY2023FY2022FY2021FY2020
Period endDec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Filing10-K10-K10-K10-K10-K
ReportedJan 7, 2025Feb 29, 2024Mar 7, 2023Jan 5, 2022Jan 25, 2021
Revenue$42.3M$0$458.0K$40.0M–
Cost of revenue–$0$346.0K––
Gross profit–$0$112.0K––
Operating expenses$196.9M$67.6M$75.9M$113.3M$74.3M
Research and development$44.6M$17.2M$49.3M$79.4M$44.5M
Selling, general and administrative$149.8M$50.4M$26.6M$33.9M$29.8M
Operating income-$154.6M-$67.6M-$75.8M-$73.3M-$74.3M
Interest expense–$2.06M$521.0K$340.0K$35.0K
Income tax$10.3M$474.0K$253.0K-$18.0K$146.0K
Net income-$173.4M-$54.4M-$68.7M-$55.6M-$65.1M
EPS, basic$-0.27$-0.09$-0.13––
EPS, diluted$-0.27$-0.09$-0.13––
Weighted shares, basic652.3M634.1M529.1M––
Weighted shares, diluted652.3M634.1M529.1M––
Margins and growth
Gross margin––24.5%––
Operating margin-365.7%–-16539.3%-183.3%–
Net margin-410.2%–-15000.2%-138.9%–
Revenue growth, year over year–−100.0%−98.9%––

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Verona Pharma plc, annual
Line itemFY2024FY2023FY2022FY2021FY2020
Period endDec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Filing10-K10-K10-K10-K10-K
ReportedJan 7, 2025Feb 29, 2024Mar 7, 2023Jan 5, 2022Jan 25, 2021
Cash and equivalents$399.8M$271.8M$227.8M$148.4M$188.0M
Short-term investments––––$0
Accounts receivable$31.5M––––
Inventory$6.25M––––
Total current assets$453.6M$289.7M$243.0M$170.1M$202.5M
Property, plant and equipment$1.10M$24.0K$73.0K$80.0K$107.0K
Goodwill$545.0K$545.0K$545.0K$545.0K$545.0K
Total assets$474.2M$308.1M$259.5M$186.6M$204.2M
Accounts payable$11.3M$3.49M$2.91M$10.0M$178.0K
Total current liabilities$42.7M$8.69M$19.0M$33.4M$14.2M
Long-term debt$120.3M$48.4M$9.77M$4.87M$4.63M
Total liabilities$269.7M$58.8M$29.0M$38.6M$19.4M
Shareholders' equity$204.6M$249.3M$230.5M$148.0M$184.9M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Verona Pharma plc, annual
Line itemFY2024FY2023FY2022FY2021FY2020
Period endDec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Filing10-K10-K10-K10-K10-K
ReportedJan 7, 2025Feb 29, 2024Mar 7, 2023Jan 5, 2022Jan 25, 2021
Operating cash flow-$122.2M-$50.2M-$59.9M-$33.3M-$45.1M
Capital expenditures$580.0K$0$29.0K$12.0K$82.0K
Free cash flow-$122.8M-$50.2M-$59.9M-$33.3M-$45.2M
Depreciation and amortization$1.06M$677.0K$636.0K$629.0K$623.0K
Stock-based compensation$41.2M$19.0M$14.1M$25.4M$22.2M
Investing cash flow-$580.0K$0-$29.0K-$12.0K$9.71M
Financing cash flow$250.8M$92.9M$140.8M-$6.12M$192.3M
Net change in cash$128.0M$43.9M$79.4M-$39.6M$157.6M
Ratio
Stock-based compensation, % of revenue97.6%–3083.2%63.6%–

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Verona Pharma plc by cover date
Cover dateShares outstandingChange in a yearFiling
Apr 23, 2025681.1M+5.0%SEC
Feb 24, 2025679.8M+5.2%SEC
Oct 28, 2024654.6M+2.4%SEC
Aug 2, 2024649.9M+2.2%SEC
May 2, 2024648.7M+2.0%SEC
Feb 23, 2024646.5M+2.3%SEC
Oct 27, 2023639.5M+5.7%SEC
Jul 27, 2023635.9M+30.4%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.